RABEPRAZOLE SODIUM- rabeprazole sodium tablet, delayed release

국가: 미국

언어: 영어

출처: NLM (National Library of Medicine)

유효 성분:

RABEPRAZOLE SODIUM (UNII: 3L36P16U4R) (RABEPRAZOLE - UNII:32828355LL)

제공처:

Bryant Ranch Prepack

관리 경로:

ORAL

처방전 유형:

PRESCRIPTION DRUG

치료 징후:

Rabeprazole Sodium Delayed-Release Tablets are indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD). For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of Rabeprazole Sodium Delayed-Release Tablets may be considered. Rabeprazole Sodium Delayed-Release Tablets are indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (GERD Maintenance). Controlled studies do not extend beyond 12 months. Rabeprazole Sodium Delayed-Release Tablets are indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with GERD in adults for up to 4 weeks. Rabeprazole Sodium Delayed-Release Tablets are indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. Most patients heal within four weeks. Rabeprazole

제품 요약:

Product: 71335-0636 NDC: 71335-0636-2 90 TABLET, DELAYED RELEASE in a BOTTLE NDC: 71335-0636-3 30 TABLET, DELAYED RELEASE in a BOTTLE NDC: 71335-0636-4 60 TABLET, DELAYED RELEASE in a BOTTLE NDC: 71335-0636-5 28 TABLET, DELAYED RELEASE in a BOTTLE

승인 상태:

Abbreviated New Drug Application

환자 정보 전단

Bryant Ranch Prepack
----------
MEDICATION GUIDE
Rabeprazole Sodium (ra-bep-ra-zole soe-dee-um) Delayed-Release Tablets
Read the Medication Guide that comes with Rabeprazole Sodium
Delayed-Release Tablets before you
start taking it and each time you get a refill. There may be new
information. This Medication Guide does
not take the place of talking to your doctor about your medical
condition or treatment.
What is the most important information I should know about Rabeprazole
Sodium Delayed-Release
Tablets?
Rabeprazole Sodium Delayed-Release Tablets may help your acid-related
symptoms, but you could still
have serious stomach problems. Talk with your doctor.
Rabeprazole Sodium Delayed-Release Tablets can cause serious side
effects, including:
•
A type of kidney problem (acute interstitial nephritis). Some people
who take proton pump
inhibitor (PPI) medicines, including Rabeprazole Sodium
Delayed-Release Tablets, may develop
a kidney problem called acute interstitial nephritis that can happen
at any time during treatment
with Rabeprazole Sodium Delayed-Release Tablets. Call your doctor if
you have a decrease in the
amount that you urinate or if you have blood in your urine.
•
Diarrhea. Rabeprazole Sodium Delayed-Release Tablets may increase your
risk of getting severe
diarrhea. This diarrhea may be caused by an infection (Clostridium
difficile) in your intestines.
Call your doctor right away if you have watery stool, stomach pain,
and fever that does not go
away.
•
Bone fractures. People who take multiple daily doses of PPI medicines
for a long period of time
(1 year or longer) may have an increased risk of fractures of the hip,
wrist, or spine. You should
take Rabeprazole Sodium Delayed-Release Tablets exactly as prescribed,
at the lowest dose
possible for your treatment and for the shortest time needed.
•
Certain types of lupus erythematosus. Lupus erythematosus is an
autoimmune disorder (the
body's immune cells attack other cells or organs in the body). Some
people who take PPI
medicines, including Rabep

제품 특성 요약

RABEPRAZOLE SODIUM- RABEPRAZOLE SODIUM TABLET, DELAYED RELEASE
BRYANT RANCH PREPACK
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
RABEPRAZOLE SODIUM DELAYED-
RELEASE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING
INFORMATION FOR RABEPRAZOLE SODIUM
DELAYED-RELEASE TABLETS.
RABEPRAZOLE SODIUM DELAYED-RELEASE TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 1999
RECENT MAJOR CHANGES
Contraindications (4)
04/2016
Warnings and Precautions, Cutaneous and Systemic Lupus Erythematosus
(5.6)
10/2016
INDICATIONS AND USAGE
Rabeprazole Sodium Delayed-Release Tablets are a proton-pump inhibitor
(PPI) indicated in adults for:
Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease
(GERD) (1.1).
Maintenance of Healing of Erosive or Ulcerative GERD (1.2).
Treatment of Symptomatic GERD (1.3).
Healing of Duodenal Ulcers (1.4).
_Helicobacter pylori_ Eradication to Reduce the Risk of Duodenal Ulcer
Recurrence (1.5).
Treatment of Pathological Hypersecretory Conditions, Including
Zollinger-Ellison Syndrome (1.6).
In adolescent patients 12 years of age and older for:
Short-term treatment of Symptomatic GERD (1.7).
DOSAGE AND ADMINISTRATION
INDIC ATIO N
RECOMMENDED DOSAGE (2)
*
Healing of Erosive or Ulcerative Gastroesophageal Reflux
Disease (GERD)
20 mg once daily for 4 to 8 weeks
Maintenance of Healing of Erosive or Ulcerative GERD
20 mg once daily
Symptomatic GERD in Adults
20 mg once daily for 4 weeks
Healing of Duodenal Ulcers
20 mg once daily after morning meal for up to 4 weeks
_Helicobacter pylori_ Eradication to Reduce the Risk of
Duodenal Ulcer Recurrence
Three Drug Regimen:
Rabeprazole Sodium Delayed-Release Tablets 20 mg
Amoxicillin 1000 mg
Clarithromycin 500 mg
_All three medications should be taken twice daily with_
_morning and evening meals for 7 days_
Pathological Hypersecretory Conditions, Including Zollinger-
Ellison Syndrome
Starting dose 60 mg once daily then adjust to patient needs
Symptomatic GERD in Adolescents 12 Years of Age and
Old